Can a hormone block food cravings? new study investigates
NCT ID NCT06845033
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether infusing a natural hormone called LEAP2 can reduce how the brain reacts to pictures of food in people with obesity. Twenty-eight men with a BMI between 30 and 50 will receive either LEAP2 or a placebo on two separate days and undergo brain scans. The goal is to understand if blocking the ghrelin receptor lowers activity in brain areas linked to appetite and reward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LEAP2 (a natural hormone that blocks the ghrelin receptor)
What this could lead to
If successful, this could point toward a new way to reduce food cravings in obesity by targeting brain appetite centers.
What could go wrong
This is a very early, small study (28 men) looking at brain scans, not weight loss. The effect may be small or not translate to real-world eating behavior.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Clinical Metabolic Research
Hellerup, 2900, Denmark